Hansa Medical AB News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

01.07.21	Hansa Biopharma to host conference call to provide interim results for first half 2021 and Business Update (PR Newswire)
12.05.21	Bulletin from the Annual General Meeting in Hansa Biopharma AB (publ) (PR Newswire)
22.04.21	Hansa Biopharma interim report Jan-Mar 2021 (PR Newswire)
14.04.21	Hansa Biopharma to host conference call to provide interim results from Q1 2021 and Business Update (PR Newswire)
09.04.21	Hansa Biopharma: Notice to Annual General Meeting (PR Newswire)
29.03.21	Hansa Biopharma enters preclinical research collaboration with argenx (PR Newswire)
01.03.21	Hansa Biopharma appoints Dr. Magnus Korsgren as Head of Research & Development (PR Newswire)
27.01.21	Hansa Biopharma to host conference call to provide Year-End report 2020 and Business Update (PR Newswire)
11.01.21	Hansa Biopharma provides business update incl. certain key financials ahead of the JP Morgan Global Healthcare Conference (PR Newswire)
23.12.20	Hansa Biopharma to present at the 39th Annual J.P. Morgan Healthcare Conference (PR Newswire)
02.11.20	Hansa Biopharma Nomination Committee formed (PR Newswire)
22.10.20	Hansa Biopharma interim report Jan-Sep 2020 (PR Newswire)
24.09.20	Hansa Biopharm announces positive high-level data from investigator-initiated phase 2 trial with imlifidase to treat anti-GBM disease (PR Newswire)
17.09.20	Hansa Biopharma to host Capital Markets Day on Thursday October 29, 2020 in Copenhagen (PR Newswire)
01.09.20	Hansa Biopharma provides updated guidance on its clinical programs (PR Newswire)
31.08.20	Hansa Biopharma announces participation in Fall conferences and an updated financial calendar (PR Newswire)
26.08.20	The EU Commission grants conditional approval for IdefirixTM (imlifidase) in highly sensitized kidney transplant patients in the European Union (PR Newswire)
31.07.20	Hansa Biopharma announces increase in number of shares and votes (PR Newswire)
16.07.20	Hansa Biopharma Interim Report Jan-Jun 2020 (PR Newswire)
02.07.20	Hansa Biopharma Announces Exclusive Agreement With Sarepta Therapeutics to Develop and Promote Imlifidase as Pre-treatment Ahead of Gene Therapy in Select Indications (PR Newswire)
02.07.20	Hansa Biopharma Announces Exclusive Agreement With Sarepta Therapeutics to Develop and Promote Imlifidase as Pre-treatment Ahead of Gene Therapy in Select Indications (PR Newswire)
30.06.20	Hansa Biopharma to Host Conference Call to Provide Interim Results for the First Half of 2020 and Business Update (PR Newswire)
25.06.20	Hansa Biopharma Receives Positive CHMP Opinion for IdefirixTM (imlifidase) for Kidney Transplant in EU (PR Newswire)
23.06.20	Bulletin from the Annual General Meeting in Hansa Biopharma AB (publ) (PR Newswire)
29.05.20	Hansa Biopharma Appoints Achim Kaufhold as CMO to Support the Expansion Outside Transplantation (PR Newswire)
25.05.20	Hansa Biopharma Submits Responses to Outstanding Questions From EMA on May 26 (PR Newswire)
20.05.20	Notice to Annual General Meeting in Hansa Biopharma AB (publ) (PR Newswire)
20.05.20	Hansa Biopharma Announces Upcoming Presentations Including a Late Breaking Poster Presentation at the 2020 American Transplant Congress (PR Newswire)
13.05.20	Hansa Biopharma to Participate in Five Upcoming Investor Conferences During May and June (PR Newswire)
28.04.20	Hansa Biopharma Interim Report Jan-Mar 2020. EMA Process on Track; an Opinion From the CHMP is Expected in the Second Quarter 2020 (PR Newswire)
15.04.20	Hansa Biopharma to Host Conference Call to Provide Interim Results for the First Quarter of 2020 and Business Update (PR Newswire)
02.04.20	Hansa Biopharma Publishes Annual Report 2019 (PR Newswire)
06.03.20	Hansa Biopharma Announces Long Term Follow-up Data That Demonstrates 2-year Graft Survival of 89% After Imlifdase Treatment and Transplantation (PR Newswire)
25.02.20	Hansa Biopharma to Participate in Two Upcoming Investor Conferences (PR Newswire)
06.02.20	Hansa Biopharma Year-End Report 2019 (PR Newswire)
27.01.20	Hansa Biopharma Completes Enrollment in Anti-GBM (PR Newswire)
22.01.20	Hansa Biopharma to Host Conference Call to Provide Year-End report 2019 and Business Update (PR Newswire)
13.01.20	Hansa Biopharma Provides Business Update Ahead of the JP Morgan Global Healthcare Conference (PR Newswire)
13.12.19	Hansa Biopharma has Agreed With the FDA on a Regulatory Path Forward for Imlifidase in Kidney Transplantation of Highly Sensitized Patients in the U.S. (PR Newswire)
19.11.19	Hansa Biopharma Nomination Committee Formed (PR Newswire)
31.10.19	Hansa Biopharma Interim Report January-September 2019 (PR Newswire)
11.10.19	Hansa Biopharma to Host Conference Call to Provide Interim Results for the First Nine Months of 2019 and Business Update (PR Newswire)
25.09.19	Hansa Biopharma Confirms Follow-up Meeting With FDA (PR Newswire)
18.09.19	Hansa Biopharma: Positive Results Presented at ESOT; Imlifidase Enabled Transplantation in 46 Sensitized Patients (PR Newswire)
02.09.19	Hansa Biopharma: Issue and Re-purchase of Class C Shares for Incentive Programme (PR Newswire)
30.08.19	Hansa Biopharma: New Imlifidase Data Presented at ESOT, Copenhagen (PR Newswire)
21.08.19	Hansa Biopharma to Participate in Three Upcoming Investor Conferences (PR Newswire)
18.07.19	Hansa Biopharma Interim Report January-June 2019 (PR Newswire)
05.07.19	Hansa Biopharma to Host Conference Call to Provide Second Quarter 2019 Business Update (PR Newswire)
07.06.19	Plenary Presentation at the 2019 American Transplant Congress Demonstrates Significant Reduction in Time on the Waitlist for Patients Treated with Imlifidase Compared to Matched Controls (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sonova Hldg	302.80	1.30 %	K V
Alcon	76.88	0.65 %	K V
Sika	218.00	0.37 %	K V
Kuehne+Nagel Int	202.60	-0.20 %	K V
Logitech Intl	78.28	-0.33 %	K V
ABB	49.25	-1.44 %	K V
Holcim	87.68	-1.55 %	K V
Zurich Insur Gr	531.20	-1.63 %	K V
Roche Hldg G	267.20	-1.69 %	K V
UBS Group	29.78	-1.94 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Hansa Medical AB

Aktien Top/Flop

Meistgelesene Nachrichten